Efficacy and safety of adjuvant capecitabine and pembrolizumab in early-stage triple-negative breast cancer after standard neo-/adjuvant chemotherapy: A meta-analysis of phase III studies
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Publicado em
- 13 jan 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of adjuvant capecitabine and pembrolizumab in early-stage triple-negative breast cancer after standard neo-/adjuvant chemotherapy: A meta-analysis of phase III studies
Wala Ben Kridis, Afef Khanfir
Descritores MeSH
- Capecitabine
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- Triple Negative Breast Neoplasms
- Neoplasm Staging
- Randomized Controlled Trials as Topic
- Treatment Outcome
- Chemotherapy, Adjuvant
- Clinical Trials, Phase III as Topic
- Disease-Free Survival
Veja também
Estudos relacionados
- Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
- Inibidores do Ponto de Controle Imune Adjuvante no Câncer de Cabeça e Pescoço: Uma Meta-Análise dos Ensaios de Fase III
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: An updated systematic review and meta-analysis
- Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical Trial